Therapeutic modalities following low-density lipoprotein cholesterol goal attainment

Bibliography

• Brown ML, Ramprasad MP, Umeda PK et al.: A macrophage receptor for apolipoprotein B48: cloning, expression, and atherosclerosis. Proc. Natl Acad. Sci. USA 97, 7488–7493 (2000)
   Google Scholar
• Yu KC, Cooper AD: Postprandial lipoproteins and atherosclerosis. Front Biosci. 6, D332–D354 (2001)
   Google Scholar
• Greene DJ, Skeggs JW, Morton RE: Elevated triglyceride content diminishes the capacity of high-density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI). J. Biol. Chem. 276, 4804–4811 (2001)
   Google Scholar
• Kwiterovich PO Jr: Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am. J. Cardiol. 90, 30i–47i (2002)
   Google Scholar
• Brewer HB Jr, Remaley AT, Neufeld EB, Basso F, Joyce C: Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 24, 1755–1760 (2004)
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al.: National Heart, Lung and Blood Institute; American College of Cardiology Foundation; American Heart Association. The Adult Treatment Panel III (implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227–239 (2004)
   Google Scholar
• Frick MH, Elo O, Haapa K et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317, 1237–1245 (1987)
   Google Scholar
• Rubins HB, Robins SJ, Collins D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341, 410–418 (1999)
   Google Scholar
• Haim M, Benderly M, Brunner D et al.: Elevated serum triglyceride levels and longterm mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation 100, 475–482 (1999)
   Google Scholar
• Keech A, Simes RJ, Barter P et al.: Effects of long-term fenofibrate therapy on cardiovascular events in people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9795), 1849–1861 (2005)
   Google Scholar
• Stamler J: The coronary drug project – findings with regard to estrogen, dextrothyroxine, clofibrate and niacin. Adv. Exp. Med. Biol. 82, 52–75 (1977)
   Google Scholar
• Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand. 223, 405–418 (1988)
   Google Scholar
• Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257, 3233–3240 (1987)
   Google Scholar
• Brown G, Albers JJ, Fisher LD et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323, 1289–1298 (1990)
   Google Scholar
• Brown BG, Zhao XQ, Chait A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345, 1583–1592 (2001)
   Google Scholar
• Miller M: Niacin as a component of combination therapy for dyslipidemia. Mayo Clin. Proc. 78, 735–742 (2003)
   Google Scholar
• Steffensen KR, Gustafsson J-A: Liver X receptors: new drug targets to treat Type 2 diabetes. Future Lipidol. 1(2), 181–189 (2006)
   Google Scholar
• Zandbergen F, van Dijk S, Müller M, Kersten S: Fasting-induced adipose factor/angiopoietin-like protein 4: a potential target for dyslipidemia? Future Lipidol. 227–236 1(2), (2006)
   Google Scholar
• Miller M, Seidler A, Moalemi A, Pearson TA: Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J. Am. Coll. Cardiol. 31, 1252–1257 (1998)
   Google Scholar
• Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 97, 1029–1036 (1998)
   Google Scholar
• Ahmad I, Zhan M, Miller M: High prevalence of C-reactive protein elevation with normal triglycerides (100–149 mg/dl): are triglyceride levels below 100 mg/dL more optimal in coronary heart disease risk assessment? Am. J. Med. Sci. 329, 173–177 (2005)
   Google Scholar
• Hopkins PN, Wu LL, Hunt SC, Brinton EA: Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J. Am. Coll. Cardiol. 45, 1003–1012 (2005).
   Google Scholar